oral semaglutide novo FDA approves Nordisk's (Rybelsus) for CV risk reduction in T2DM adults Novo says it's submitted obesity

-

CMS.gov, Medicare GLP-1 Weight Loss Drug Access Program Medicare vs

Semaglutide was first approved by the FDA for weight loss under the name of Wegovy in June of 2014

Taking control of your health requires a trusted medical partner that prioritizes your comfort, safety, and individual needs

Although Novo Nordisk holds trademarks for Ozempic and Wegovy, it is unclear whether advertising compounded semaglutide products, even including a reference to Ozempic and Wegovy in the ad, truly creates any consumer confusionand it likely will remain unclear until there is a case that is fully litigated. Disclosure: Armin Ghiam has represented defendants against claims asserted by Novo Nordisk